A Combined Phase 0/2 "Trigger" Trial Evaluating Pamiparib or Olaparib with Concurrent Radiotherapy in Patients with Newly-Diagnosed or Recurrent Glioblastoma

W.R. Kennedy, Y.W. Chang, J. Jiang,J. Molloy,C. Pennington-Krygier,J. Harmon,A. Hong,J. Wanebo, K. Braun,M.A. Garcia,I.J. Barani Jr,W. Yoo,A. Tovmasyan,A.C. Tien, J. Li,S. Mehta,N. Sanai

International journal of radiation oncology, biology, physics（2023）

Cited 0|Views11

No score

Abstract

Pamiparib achieved pharmacologically-relevant concentrations in nonenhancing GBM tissue and suppressed induction of PAR levels ex vivo post-radiation. The majority of patients with MGMT-unmethylated GBM advanced to the phase 2 portion of the trial, and pamiparib was generally well-tolerated in these patients.

Translated text

Key words

trial evaluating pamiparib,concurrent radiotherapy,olaparib,newly-diagnosed

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined